Reaction equation
Br[C:2]1[S:6][C:5]([NH:7][C:8]([NH:10][C:11]2[CH:16]=[CH:15][C:14]([CH3:17])=[CH:13][C:12]=2[C:18]([CH:20]2[CH2:24][CH2:23][CH2:22][CH2:21]2)=[O:19])=[O:9])=[N:4][CH:3]=1.[C:25]([O:29][C:30](=[O:35])[NH:31][CH2:32][CH2:33][SH:34])([CH3:28])([CH3:27])[CH3:26]>>[C:25]([O:29][C:30](=[O:35])[NH:31][CH2:32][CH2:33][S:34][C:2]1[S:6][C:5]([NH:7][C:8]([NH:10][C:11]2[CH:16]=[CH:15][C:14]([CH3:17])=[CH:13][C:12]=2[C:18]([CH:20]2[CH2:24][CH2:23][CH2:22][CH2:21]2)=[O:19])=[O:9])=[N:4][CH:3]=1)([CH3:28])([CH3:26])[CH3:27]Participants
3
Procedure
(2-{2-[3-(2-Cyclopentanecarbonyl-4-methyl-phenyl)-ureido]-thiazol-5-ylsulfanyl}-ethyl)-carbamic acid tert-butyl ester (202 mg, 40%) was prepared from 1-(5-bromo-thiazol-2-yl)-3-(2-cyclo pentanecarbonyl-4-methyl-phenyl)-urea (408 mg, 1 mmol) and (2-mercapto-ethyl)-carbamic acid tert-butyl ester (354 mg, 2 mmol) following the general procedure Q.
Sources & evidence
- ORD record
- ord-082bccc895d54922b93e3b88bc687bc0
- Source dataset
- uspto-grants-2011_03
- Patent number
- US07897628B2
Linked notes
Loading…